Targeting the oxidative stress-neuroinflammation axis: the mechanism of arctigenin's broad-spectrum analgesia with limited side effects - PubMed
4 hours ago
- #neuropathic pain
- #analgesia
- #arctigenin
- Arctigenin (AG) shows anti-inflammatory effects in glucose, lipid metabolism, and type 2 diabetes.
- AG exhibits dose-dependent antinociceptive effects in spared nerve injury (SNI)-induced neuropathic pain in mice.
- AG inhibits ERK, JNK, and p38 phosphorylation in the lumbar spinal cord but not AMPK, PGC-α, and mTOR pathways.
- AG's analgesic effects are blocked by pretreatment with U0126, SB203580, or SP600125.
- AG relieves pain by restoring mitochondrial biogenesis, inhibiting oxidative damage, and suppressing microglia and astrocyte activation.
- AG decreases pro-inflammatory factors, contributing to neuronal modulation.
- Minocycline pretreatment reduces but does not completely block AG's analgesic effect, indicating microglia activation is not essential.
- AG shows broad-spectrum analgesic properties across diverse pain models.
- Prolonged AG injection has no hepatic or renal side effects and avoids typical analgesic side effects like tolerance, addiction, or constipation.
- AG is a novel therapeutic target for neuropathic pain with high efficacy and low side effects.